Table 3.

Secondary outcomes

HDP category	Placebo N=192	Furosemide N=192	Relative Risk (RR)	aRR* (95% CI)	p-value
Hypertension related hospital readmissions/emergency room visits	16 (8)	9 (5)	0.56 (0.25–1.24)	0.55 (0.25–1.21)	0.14
Percentage of postpartum blood pressures in the severe range† (%)	6.8	6.6	0.86 (0.27–2.71)	0.81 (0.26–2.57)	0.36
Overall need for any antihypertensive medication postpartum (at time of discharge or post-discharge)	62 (32)	63 (33)			0.91
Discharged on antihypertensive medication	22 (11)	40 (21)	1.82 (1.12–2.94)	1.67 (1.04–2.68)	0.04
Required new or additional antihypertensive medication after discharge	39 (20)	25 (13)	0.64 (0.40–1.02)	0.61 (0.39–0.96)	0.03
Pulmonary edema	1 (1)	3 (2)	3 (0.32–28.59)	2.07 (0.22–19.18)	0.52
Postpartum length of stay (days)‡	2 (2–2)	2 (2–3)	0.15 (−0.02–0.32)	0.02 (−0.09–0.13)	0.76
Adverse effects associated with furosemide	4 (2)	0	--	--	--
NICU admission	0 (0)	2 (1)	--	--	0.25
Reported breast-feeding issues	9 (6)	4 (3)	0.46 (0.15–1.47)	--	0.26
Systolic blood pressure at 6 weeks postpartum (mm Hg)‡	120 (112–128)	120 (110–124)	−1.94 (−4.93 – 1.05)	--	0.25
Blood pressure ≥140/90 at 6 weeks postpartum	13 (13)	10 (10)	0.78 (0.36–1.71)	0.78 (0.36–1.69)	0.53
Blood pressure ≥130/80 at 6 weeks postpartum	48 (47)	41 (41)	0.87 (0.64–1.19)	0.87 (0.64–1.19)	0.38

^*Adjusted for mode of delivery

^†Frequency of severe hypertension defined as: SBP ≥160 mmHg or DBP ≥110 mmHg

NICU: neonatal intensive care unit

Data are presented as n (%) except where indicated

^‡Median [Inter-quartile range]